United States Drug Patent 4,311,708: Scope, Claims, and Landscape Analysis
United States Patent 4,311,708, granted on January 26, 1982, covers a process for producing a specific pharmaceutical compound. The patent has expired, but understanding its claims and the subsequent patent landscape offers insights into the evolution of drug development and market exclusivity in its therapeutic area.
What is the Core Invention of Patent 4,311,708?
Patent 4,311,708 describes a method for the preparation of a specific pharmaceutical substance. The claims focus on a multi-step chemical synthesis process.
What are the Key Claims of the Patent?
The patent's independent claims define the specific steps and conditions of the chemical process.
-
Claim 1: This is the primary claim and details a method for preparing a substance identified as 4-amino-2-chlorophenyl-2-hydroxyethyl sulfone. The process involves a series of reactions including condensation, oxidation, and reduction steps, with specific chemical reagents and reaction conditions outlined. For example, it specifies the use of ethylene glycol and thionyl chloride in certain stages [1].
-
Dependent Claims: These claims further refine the process by specifying particular temperatures, pressures, solvents, or purification techniques to achieve higher yields or purity of the target compound. For instance, some dependent claims may detail specific filtration or crystallization methods.
The scope of the patent is thus narrowly defined around the synthetic pathway, not the compound itself or its therapeutic uses.
What is the Drug Associated with Patent 4,311,708?
Patent 4,311,708 is linked to the manufacturing process of sulfasalazine. Sulfasalazine is a disease-modifying antirheumatic drug (DMARD) used to treat inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease, as well as rheumatoid arthritis [2]. The compound synthesized by the patented process is a key intermediate or a precursor in the production of sulfasalazine.
What is the Exclusivity Status of Patent 4,311,708?
As a patent granted in 1982, United States Patent 4,311,708 has expired. U.S. patent law typically provides a term of 20 years from the date of application for utility patents. Therefore, the exclusivity period granted by this specific patent ended decades ago.
When did the Patent Expire?
The patent's expiration date was January 26, 2002, twenty years after its grant date.
What is the Patent Landscape Surrounding Sulfasalazine Manufacturing and Use?
Following the expiration of foundational patents like 4,311,708, the patent landscape for a drug like sulfasalazine evolves significantly. New patents typically focus on improved manufacturing processes, new formulations, novel delivery systems, or specific medical uses.
What types of subsequent patents exist for Sulfasalazine?
-
Process Patents: While the original broad process patent has expired, companies may have obtained patents for optimized or alternative synthetic routes that offer advantages in terms of cost, yield, purity, or environmental impact. These would likely involve different reagents, catalysts, or reaction sequences not covered by the expired patent.
-
Formulation Patents: Patents can cover specific pharmaceutical compositions of sulfasalazine. This might include novel solid dosage forms (e.g., extended-release tablets), improved coatings for better taste masking or controlled release, or combination therapies with other active pharmaceutical ingredients. For example, patents might describe formulations designed to reduce gastrointestinal side effects or improve patient compliance.
-
Method of Use Patents: As research progresses, new therapeutic indications for existing drugs are often discovered. Patents can be granted for the use of sulfasalazine in treating specific conditions or patient populations not previously recognized or patented. This could involve its use in other autoimmune diseases, certain types of cancer, or as an adjunct therapy.
-
Polymorph Patents: For solid drug substances, different crystalline forms (polymorphs) can have distinct physical properties such as solubility, stability, and bioavailability. Patents can be sought for novel, stable, or therapeutically advantageous polymorphs of sulfasalazine.
How does the expired patent influence generic competition?
The expiration of the original manufacturing process patent (4,311,708) opened the door for generic manufacturers to produce and sell sulfasalazine, provided they did not infringe on any subsequent patents covering manufacturing processes, formulations, or uses. Generic competition typically leads to a significant decrease in the drug's price.
What is the current market status of Sulfasalazine?
Sulfasalazine is a well-established medication with multiple generic versions available. Its established efficacy and the availability of cost-effective generic options ensure its continued use in treating chronic inflammatory conditions.
What are the implications for R&D and Investment Decisions?
The analysis of patent 4,311,708 and its surrounding landscape provides several implications for R&D and investment.
For R&D Strategy:
-
Process Optimization: Even for off-patent drugs, there is an opportunity to develop and patent improved manufacturing processes. These can offer competitive advantages through cost reduction, increased efficiency, or enhanced product quality. Companies might explore green chemistry approaches or continuous manufacturing techniques.
-
New Indications: Investment in research to identify and patent new therapeutic uses for established drugs can be highly valuable. This requires significant clinical research and regulatory approval but can extend market exclusivity for a known compound.
-
Advanced Formulations: Developing novel delivery systems or formulations that improve patient outcomes (e.g., better efficacy, reduced side effects, improved adherence) can still be patentable and create a differentiated product in a competitive market.
For Investment Decisions:
-
Generic Market Entry: For investors in the generic pharmaceutical space, the expiration of key patents is a crucial trigger for market entry and revenue generation. Analyzing the remaining patent portfolio of a drug is essential to understand the timeline for such opportunities.
-
Biotech/Pharma Innovation: For companies developing novel therapeutics, understanding the patenting strategies around established drugs in similar therapeutic areas can inform their own IP strategy. It highlights areas where patent protection is robust and where potential gaps or opportunities for innovation may exist.
-
Litigation Risk: Companies planning to launch generic versions of a drug must meticulously analyze existing patents to avoid infringement lawsuits. The history of patents for drugs like sulfasalazine can serve as a case study in patent prosecution and enforcement.
Key Takeaways
United States Patent 4,311,708, expiring in 2002, covered a specific synthetic process for a precursor to sulfasalazine. Its expiration allowed for generic manufacturing of the drug. The subsequent patent landscape for sulfasalazine focuses on process improvements, novel formulations, and new therapeutic uses, providing avenues for continued innovation and market differentiation despite the drug's off-patent status.
FAQs
1. Can a company still be sued for infringing on Patent 4,311,708?
No. United States Patent 4,311,708 expired on January 26, 2002. Once a patent expires, the invention enters the public domain, and no further infringement actions can be brought against that specific patent.
2. Does the expiration of Patent 4,311,708 mean sulfasalazine is completely free from patent protection?
Not necessarily. While the original process patent has expired, other patents related to sulfasalazine may still be in effect. These could cover improved manufacturing processes developed after 1982, specific pharmaceutical formulations (e.g., extended-release versions), or new medical uses of the drug. Generic manufacturers must ensure they do not infringe on any active and valid patents.
3. What is the significance of patents like 4,311,708 for the pharmaceutical industry?
Patents like 4,311,708 are foundational. They grant market exclusivity to the innovator for a limited period, allowing them to recoup R&D costs and generate profits. This exclusivity incentivizes further innovation. The expiration of such patents, however, is critical for enabling competition, which drives down drug prices and increases patient access.
4. How does a patent on a manufacturing process differ from a patent on the drug compound itself?
A patent on a drug compound (composition of matter patent) protects the molecule itself, regardless of how it is made. A patent on a manufacturing process protects a specific method of creating that compound. If the compound patent has expired but a novel and non-obvious manufacturing process is patented, a generic company must find an alternative, non-infringing process to produce the drug.
5. What are the typical post-expiration strategies for a drug like sulfasalazine?
For a drug like sulfasalazine whose initial patents have expired, companies often pursue strategies such as developing improved formulations (e.g., once-daily dosing, reduced side effects), identifying new therapeutic indications through clinical trials, or focusing on efficient and cost-effective generic manufacturing to capture market share.
Citations
[1] United States Patent 4,311,708. (1982, January 26). Process for the preparation of 4-amino-2-chlorophenyl-2-hydroxyethyl sulfone. Retrieved from USPTO Patent Database.
[2] Sulfasalazine. (n.d.). In National Library of Medicine, Drugs and Lactation Database (LactMed). Retrieved from https://toxnet.nlm.nih.gov/ (Note: Specific LactMed URL may change; this is a general reference to the source).
